ACCELERANT HOLDINGS (ARX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $14.24, ACCELERANT HOLDINGS (ARX) is priced for 25.9% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-07-25 · Source: https://boothcheck.com/report/ARX

Headline

FieldValue
TickerARX
CompanyACCELERANT HOLDINGS
Sector / IndustryFinancial Services
Current price$14.24/sh
CompositionExchange Services 33% / MGA Operations 25% / Underwriting 42%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Price-to-book4.56x
Return on equity now8.9%

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 17.8% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

Solve inputs: computed at a 8.8% cost of equity; ROE searched up to the 17.8% ROE ceiling.

How unusual the bet is: extreme

ReferenceValue
cohort percentile (of 91 peers)90
sustained it ~10 years at this level46%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset4.82x2expensive
Earnings—0—
Relative2.81x1expensive
Growth1.24x2expensive

Families that justify the price: Growth Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)———no—
Relative ValuationRelative$5.072.81xyesP/S fallback (negative EPS): Sector P/S 1.2x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$3.124.56xyesBook value floor: BV/sh $3.12, ROE negative
Two-Stage Excess ReturnAsset$2.815.07xyesBook value with convergence: BV/sh $3.12, ROE converges to ke
Discounted Future Market CapGrowth$20.660.69xyesRev $0.9B, growth 30% (input: historical growth; tapered), Terminal P/S: 2.7x / 3.4x / 4.0x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$7.941.79xyesMargin ramp: -50% → 10% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

One number decides this company: how much premium flows across the exchange. Everything else is downstream of it. Exchange Written Premium reached $4.19 billion in 2025, and the 10-K reports that the platform carried 280 Members and 95 Risk Capital Partners at year end after growing that premium at a 187% compounded annual growth rate since inception. If the flow keeps compounding, the fee businesses bolted to it compound with it. If it stalls, nothing else in the model rescues the result.

The structure is worth a moment because it is not what the sector usually looks like. Accelerant sits between specialty underwriters who originate risk and the reinsurers who fund it. Its filing describes Exchange Services, which is the core of Accelerant, as well as MGA Operations and Underwriting, and notes that Exchange Services and MGA Operations are both fee-based businesses. Underwriting is the largest of the three at about 42% of revenue, with Exchange Services about 33% of revenue and MGA Operations about 25% of revenue. Fee income does not need capital standing behind it the way underwritten risk does, and that is why the economics can look unlike an insurer's.

The operating trajectory has been steep. Total revenues were $912.9 million in 2025 against $602.6 million in 2024 and $344.0 million in 2023. On the company's own adjusted measure, earnings before interest, tax, depreciation and amortisation rose to $281.8 million from $113.0 million and then $36.1 million across those three years, lifting the adjusted margin to 31% from 19% and 10%.

What makes the flow durable is that each side needs what the other holds. A specialty underwriter with a good book needs capacity; a reinsurer with capacity needs underwriting it can trust. The filing is direct about the depth on the funding side, describing partners with substantial balance sheets that have the capacity to support the pace of our growth and could singularly support our entire portfolio today. A platform where any single funder could carry the entire book is not a platform with a funding problem.

Among the listed peers, Palomar Holdings (PLMR) grew revenue about 60.7% on a base of $980.3 million, Lemonade (LMND) about 51.2% on $844.7 million, and KINSALE CAPITAL GROUP (KNSL) about 17.0% on $1,917.3 million. Accelerant's own revenue went from $602.6 million to $912.9 million over the same stretch, which puts its growth in the top half of that group. It does so without the profitability record any of the mature names carry, which is precisely the trade on offer.

What the price is buying is that this compounds well past the point where financial businesses usually stop. That is a demanding bet, and it is not an incoherent one. A fee-based exchange is not capital-constrained the way a balance-sheet insurer is, so the ceiling on how fast it can grow is different in kind rather than merely higher. The bull argument is that the ceiling the standard frames impose was written for a different sort of company.

Bear Case

Look first at what happened at the flotation, because it is the largest single fact in the accounts. In July 2025 Accelerant distributed 65,270,453 Class A shares to officers and employees and booked a non-cash profits-interest distribution expense of roughly $1.38 billion against it. That charge is why total expenses came to $2,234.8 million against total revenues of $912.9 million, and why the year closed with a pre-tax loss of $1,321.9 million. The company's position is that the charge does not recur and was matched by a corresponding capital contribution, and both of those statements are true. It is also true that a company sold stock to the public at $21 a share and, in the same motion, handed its own people a block roughly twice the size of the offering.

Control did not change hands at the listing either. The filing states that Altamont Capital has a significant influence in determining the outcome of any corporate transaction or other matter submitted to the shareholders for approval, including mergers, consolidations, the election of directors and other significant corporate actions. A public holder here is a minority partner in a company whose direction somebody else settles.

Some of the revenue also sits closer to home than the platform framing implies. The filing records that the rise in direct commission income from affiliated entities accounted for $51.8 million of the year-over-year growth in revenue, and management has been steering business away from the affiliated carrier toward outside insurers, which reached 41% of exchange written premium by the March quarter of 2026. The direction of travel is the right one. The starting point is still the point.

Then there is what the shares cost. At $14.24 they change hands at about 4.6 times book value, which is the top of the specialty-insurance peer group rather than a place inside it. For an insurance business that multiple is a statement about what the company earns on the capital it holds, and the level required to support this one sits beyond the top of the band that even the most consistently profitable insurers have delivered, held there for four decades. Nobody has forecast that. It is simply what falls out if you start from the quoted number and work backwards.

None of which says the exchange does not work. It plainly does, the premium flow is real, and the fee businesses attached to it are growing quickly. The bear case is narrower and harder to dismiss: a business growing at this rate is priced as though the rate persists, while the filing itself sets the opposite expectation, stating that we expect our annual growth rate to moderate. When a company is priced at the very top of its peer group on book value, moderation is not a soft landing. Moderation is the risk.

Valuation

An insurance business is priced off what it earns on the capital it holds, so the lens here is book value rather than an earnings multiple, and the reading is stark. At $14.24 the shares trade at about 4.6 times book, which sits at the very top of the specialty-insurance peer group rather than anywhere inside it. Book value itself is roughly $3.12 a share.

What that multiple demands cannot be resolved into a single number, and that is itself the finding. To support it, the business would have to earn a return on its capital beyond the top of the range even the most consistently profitable insurers have delivered, and then hold it there for four decades. There is no path inside the ordinary bounds of the industry that arrives at this quotation. The honest statement is the bound, not a point estimate.

The methods say the same thing in another register. Only the forward-looking cash-flow methods reach into its neighbourhood, and the price still sits about 24% above those methods. The asset-value methods land at a small fraction of it, and the peer-multiple read is nowhere close either. When one group of approaches reaches a price and the others are not in the conversation, the price is a bet on durability that the static frames structurally cannot express. That is a real category of bet, and it is also the category with the widest spread of outcomes.

The filed inputs behind all of it are unambiguous. Total revenues were $912.9 million in 2025 against $602.6 million in 2024. Total expenses were $2,234.8 million, producing a pre-tax loss of $1,321.9 million, almost all of which was the one-off non-cash charge booked when shares were distributed at the flotation. Strip that charge out and the year was profitable on the company's own adjusted measure, at $281.8 million of adjusted earnings before interest, tax, depreciation and amortisation. Both descriptions of 2025 are accurate, and a reader needs both of them.

Against the peer group the comparison that matters is not revenue but what a dollar of book fetches. KINSALE CAPITAL GROUP (KNSL) converts about 27.5% of $1,917.3 million of revenue into net profit, and Palomar Holdings (PLMR) about 20.1% of $980.3 million. Those are the specialty insurers carrying the kind of record this multiple implies, and Accelerant does not have that record yet because it has not existed long enough to. The balance-sheet frame that fits here is regulatory capital rather than corporate leverage, and the two fee-based segments carry very little of it, which is the structural reason the downside in this name is a question about growth rather than about survival.

Catalysts

The first quarter of 2026 gave the market its first clean look at the business with the flotation charges out of the way. Revenue was $273.3 million, up 54% on the year, and Exchange Written Premium grew 16% to $1.14 billion, a fourth consecutive quarter above a billion. Management said the quarter came in ahead of plan across all six of the measures it steers by, and raised the full-year outlook on the back of it.

The revised guidance is specific enough to be tested. For 2026 the company now points to at least $5.2 billion of exchange written premium, at least $2.3 billion of third-party written premium, and at least $285 million of adjusted earnings before interest, tax, depreciation and amortisation, about $276 million of which is fee-based. For the June quarter it guided to exchange written premium of $1.27 billion to $1.32 billion and adjusted earnings on the same measure of $60 million to $66 million.

The mix shift, not the headline growth rate, is the item worth following. Third-party premium reached 41% of exchange written premium in the quarter as management moved volume away from the affiliated carrier and toward outside insurers. That transition is the difference between a genuine exchange and a distribution arm for a related balance sheet, and it is the specific thing today's multiple is paying for. The June quarter is where it either continues or it does not.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Accelerant FY2025 annual report, March 2026 · Accelerant IPO prospectus, July 2025, and FY2025 annual report · Accelerant first-quarter 2026 results, May 2026 · Accelerant 2026 outlook, May 2026 · Accelerant second-quarter 2026 guidance, May 2026

View the full interactive ARX report on boothcheck